JP2014521089A5 - - Google Patents

Download PDF

Info

Publication number
JP2014521089A5
JP2014521089A5 JP2014520229A JP2014520229A JP2014521089A5 JP 2014521089 A5 JP2014521089 A5 JP 2014521089A5 JP 2014520229 A JP2014520229 A JP 2014520229A JP 2014520229 A JP2014520229 A JP 2014520229A JP 2014521089 A5 JP2014521089 A5 JP 2014521089A5
Authority
JP
Japan
Prior art keywords
ndpoi
antibody
bead
complex
capture antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014520229A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014521089A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/045886 external-priority patent/WO2013009667A1/en
Publication of JP2014521089A publication Critical patent/JP2014521089A/ja
Publication of JP2014521089A5 publication Critical patent/JP2014521089A5/ja
Pending legal-status Critical Current

Links

JP2014520229A 2011-07-13 2012-07-09 液体試料中のアミロイドベータオリゴマーの検出方法およびその使用 Pending JP2014521089A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161507332P 2011-07-13 2011-07-13
US61/507,332 2011-07-13
PCT/US2012/045886 WO2013009667A1 (en) 2011-07-13 2012-07-09 Method for detection of amyloid beta oligomers in a fluid sample and uses thereof

Publications (2)

Publication Number Publication Date
JP2014521089A JP2014521089A (ja) 2014-08-25
JP2014521089A5 true JP2014521089A5 (enExample) 2015-08-27

Family

ID=47506433

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014520229A Pending JP2014521089A (ja) 2011-07-13 2012-07-09 液体試料中のアミロイドベータオリゴマーの検出方法およびその使用

Country Status (13)

Country Link
US (2) US20130052670A1 (enExample)
EP (2) EP2732286A4 (enExample)
JP (1) JP2014521089A (enExample)
KR (1) KR20140072019A (enExample)
CN (1) CN103782171B (enExample)
AU (1) AU2012282825B2 (enExample)
BR (1) BR112014000671A2 (enExample)
CA (1) CA2840976A1 (enExample)
DK (1) DK2732289T3 (enExample)
ES (1) ES2666840T3 (enExample)
MX (1) MX2014000480A (enExample)
RU (1) RU2014105172A (enExample)
WO (2) WO2013009667A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3449926T3 (da) 2009-06-17 2019-11-11 Biogen Ma Inc Sammensætninger og fremgangsmåder til modulering af smn2-splejsning hos et individ
US9320793B2 (en) * 2010-07-14 2016-04-26 Acumen Pharmaceuticals, Inc. Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
WO2014110291A1 (en) 2013-01-09 2014-07-17 Isis Pharmaceuticals, Inc. Compositions and methods for modulation of smn2 splicing in a subject
AU2014352944A1 (en) * 2013-11-20 2016-06-16 The General Hospital Corporation Methods and compositions for treating amyloid deposits
EP3797780B1 (en) 2014-04-17 2022-09-14 Biogen MA Inc. Compositions and methods for modulation of smn2 splicing in a subject
WO2015175769A1 (en) 2014-05-15 2015-11-19 Biogen Ma Inc. Methods for the detection of amyloid beta oligomers in biological samples
US10436802B2 (en) 2014-09-12 2019-10-08 Biogen Ma Inc. Methods for treating spinal muscular atrophy
MA41480A (fr) * 2014-10-17 2017-12-19 Glenmark Pharmaceuticals Sa Anticorps qui se lient au ccr6 et leurs utilisations
WO2017033152A1 (en) * 2015-08-25 2017-03-02 Prothena Biosciences Limited Methods for detecting phosphorylated alpha-synuclein
JP6320651B2 (ja) 2016-02-08 2018-05-09 シスメックス株式会社 被検物質の検出方法および被検物質の検出用試薬キット
WO2017218884A1 (en) 2016-06-16 2017-12-21 Ionis Pharmaceuticals, Inc. Combinations for the modulation of smn expression
JP7299566B2 (ja) * 2019-07-05 2023-06-28 株式会社島津製作所 アミロイドベータに対するモノクローナル抗体、及びその抗体を用いるアミロイドベータ関連ペプチドの測定方法
KR20220148230A (ko) 2020-02-28 2022-11-04 아이오니스 파마수티컬즈, 인코포레이티드 Smn2를 조절하기 위한 화합물 및 방법
KR102798206B1 (ko) * 2021-06-25 2025-04-22 장재원 동적 형광 또는 x-선의 표준편차와 자기상관을 활용한 조기 진단 시스템
US20240358805A1 (en) * 2021-08-30 2024-10-31 The Brigham And Women's Hospital, Inc. Methods and materials to treat neurodegenerative disease
WO2024026413A2 (en) * 2022-07-27 2024-02-01 Durin Technologies, Inc. Early detection and monitoring of neurodegenerative diseases using a multi-disease diagnostic platform
CN117589996A (zh) * 2022-08-09 2024-02-23 深圳智源生物医药有限公司 强毒性淀粉样蛋白寡聚体的诊断用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4665024A (en) 1984-10-01 1987-05-12 Becton, Dickinson And Company Fluorescent gram stain
US6218506B1 (en) 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
US6082205A (en) 1998-02-06 2000-07-04 Ohio State University System and device for determining particle characteristics
ATE445639T1 (de) 1999-08-04 2009-10-15 Univ Southern California Globularer aufbau vom amyloid-beta- protein und deren verwendungen
CN1871517A (zh) * 2002-02-19 2006-11-29 免疫公司 快速有效分离循环癌细胞的方法和试剂
US7807157B2 (en) 2004-02-20 2010-10-05 Intellect Neurosciences Inc. Monoclonal antibodies and use thereof
AU2005231364A1 (en) * 2004-04-02 2005-10-20 Merck & Co., Inc. Methods for detecting substances which bind to the amyloid precursor protein or beta amyloid fragments, and binding compounds
US7572640B2 (en) 2004-09-28 2009-08-11 Singulex, Inc. Method for highly sensitive detection of single protein molecules labeled with fluorescent moieties
EP2465872A3 (en) 2004-10-25 2012-12-19 Merck Sharp & Dohme Corporation Anti-ADDL antibodies and uses thereof
US7731962B2 (en) 2005-02-14 2010-06-08 Merck & Co., Inc. Anti-ADDL monoclonal antibody and use thereof
RU2008120027A (ru) * 2005-10-21 2009-11-27 Мерк энд Ко., Инк. (US) Анти-addl моноклональное антитело и его применение
US20090181359A1 (en) * 2007-10-25 2009-07-16 Lou Sheng C Method of performing ultra-sensitive immunoassays
JP2013511734A (ja) * 2009-11-24 2013-04-04 プロビオドルグ エージー アルツハイマー病又は軽度認知障害の診断のための新規診断方法
EP2576617B1 (en) * 2010-06-04 2016-04-27 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Universitätsmedizin MONOCLONAL ANTIBODIES TARGETING Aß OLIGOMERS
ES2573135T3 (es) * 2010-07-14 2016-06-06 Merck Sharp & Dohme Corp. Anticuerpo monoclonal anti-ADDL y usos del mismo
US9320793B2 (en) * 2010-07-14 2016-04-26 Acumen Pharmaceuticals, Inc. Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42

Similar Documents

Publication Publication Date Title
JP2014521089A5 (enExample)
RU2014105172A (ru) Способ обнаружения олигомеров бета-амилоида в образце жидкости организма и варианты его применения
JP2010516678A5 (enExample)
JP2020521951A5 (enExample)
JP2017184729A5 (enExample)
JP2017524130A5 (enExample)
JP2020517919A5 (enExample)
JP2017505897A5 (enExample)
JP2013511735A5 (enExample)
WO2014037588A3 (en) Methods and compounds for preventing, treating and diagnosing an inflammatory condition
JP2013524774A5 (enExample)
JP2016118568A5 (enExample)
KR20160029869A (ko) 질병의 발달을 모니터링하고 치료의 효율을 평가하기 위한 새로운 바이오마커
JP2017522555A5 (enExample)
JP2014517308A5 (enExample)
WO2009111254A3 (en) A rapid and sensitive method for quantitative determination of the level of heparin-pf4 complex induced immunoglobulin antibodies
Leng et al. mTOR activation induces endolysosomal remodeling and nonclassical secretion of IL-32 via exosomes in inflammatory reactive astrocytes
JP2009515183A5 (enExample)
WO2015048804A3 (en) Protein biomarker and uses thereof
JP6420475B2 (ja) 細気管支炎後の喘息の診断のためのマーカーおよびその用途
JP2016526167A5 (enExample)
EA201490576A1 (ru) Молекулярный маркер для ранней диагностики мезотелиомы плевры у пациентов и способы для анализа его экспрессии
Nyawira Maranga et al. IL‐6 is upregulated in late‐stage disease in monkeys experimentally infected with Trypanosoma brucei rhodesiense
Steiss et al. Monitoring of omalizumab therapy by measuring free IgE using a bedside immunoassay
WO2007005627A8 (en) Tuberculosis antigen detection assays and vaccines